Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Healthcare-Associated Infections Due to Multidrug-Resistant Organisms: a Surveillance Study on Extra Hospital Stay and Direct Costs

Author(s): Guglielmo Giraldi, Marzietta Montesano, Christian Napoli, Paola Frati, Raffaele La Russa, Alessandro Santurro, Matteo Scopetti and Giovanni B. Orsi*

Volume 20, Issue 8, 2019

Page: [643 - 652] Pages: 10

DOI: 10.2174/1389201020666190408095811

Price: $65

Abstract

Background: The increasing antimicrobial resistance poses a challenge to surveillance systems and raises concerns about the impact of multidrug-resistant organisms on patient safety.

Objective: The study aimed to estimate extra hospital stay and economic burden of infections due to alert organisms - mostly multidrug-resistant - in a teaching hospital.

Methods: The present retrospective matched cohort study was conducted based on the analysis of hospital admissions at Sant’Andrea Teaching Hospital in Rome from April to December 2015. Extra hospital stay was the difference in the length of stay between each case and control. All the patients developing an infection due to an alert organism were considered cases, all others were eligible as controls. The costs of LOS were evaluated by multiplying the extra stay with the hospital daily cost.

Results: Overall, 122 patients developed an infection due to alert organisms and were all matched with controls. The attributable extra stay was of 2,291 days (mean 18.8; median 19.0) with a significantly increased hospitalization in intensive care units (21.2 days), bloodstream infections (52.5 days), and infections due to Gram-negative bacteria (mean 29.2 days; median 32.6 days). Applying the single day hospital cost, the overall additional expenditure was 11,549 euro per patient. The average additional cost of antibiotic drugs for the treatment of infections was about 1,200 euro per patient.

Conclusion: The present study presents an accurate mapping of the clinical and economic impact of infections attributable to alert organisms demonstrating that infections due to multidrug-resistant organisms are associated with higher mortality, longer hospital stays, and increased costs.

Article Highlights Box: The increasing antimicrobial resistance poses a challenge for surveillance systems and raises concerns about the impact of multidrug-resistant organisms on patient safety.

• Healthcare-associated infections (HAIs) have historically been recognized as a significant public health problem requiring close surveillance.

• Despite several and reliable findings have been achieved on clinical issues, our knowledge on the economic impact of healthcare-associated infections due to multidrug-resistant organisms needs to be widened.

• Estimating the cost of infections due to multidrug-resistant organisms in terms of extra hospital stay and economic burden is complex, and the financial impact varies across different health systems.

• Evaluations of social and economic implications of hospital infections play an increasingly important role in the implementation of surveillance systems.

• The costs of infection prevention and control programs and dedicated personnel are relatively low and self-sustainable when efficient.

Keywords: Healthcare-associated infections, antimicrobial resistance, alert organisms, length of stay, cost analysis, surveillance, epidemiology.

« Previous Next »
Graphical Abstract

[1]
Anderson, D.J.; Kirkland, K.B.; Kaye, K.S.; Thacker, P.A., II; Kanafani, Z.A.; Auten, G.; Sexton, D.J. Underresourced hospital infection control and prevention programs: Penny wise, pound foolish? Infect. Control Hosp. Epidemiol., 2007, 28(7), 767-773.
[2]
Fukuda, H.; Lee, J.; Imanaka, Y. Variations in analytical methodology for estimating costs of hospital-acquired infections: A systematic review. J. Hosp. Infect., 2011, 77, 93-105.
[3]
Stone, P.W.; Braccia, D.; Larson, E. Systematic review of economic analyses of health care-associated infections. Am. J. Infect. Control, 2005, 33, 501-509.
[4]
Tansarli, G.S.; Karageorgopoulos, D.E.; Kapaskelis, A.; Falagas, M.E. Impact of antimicrobial multidrug resistance on inpatient care cost: An evaluation of the evidence. Expert Rev. Anti Infect. Ther., 2013, 11(3), 321-331.
[5]
Barbaro, S.; De Rosa, F.G.; Charrier, L.; Silvestre, C.; Lovato, E.; Gianino, M.M. Three methods for estimating days of hospitalization because of hospital-acquired infection: a comparison. J. Eval. Clin. Pract., 2012, 18(4), 776-780.
[6]
Orsi, G.B.; Di Stefano, L.; Noah, N.D. Hospital-acquired, laboratory confirmed bloodstream infection: Increased hospital stay and direct costs. Infect. Control Hosp. Epidemiol., 2002, 23(4), 190-197.
[7]
Greco, D.; Moro, M.L.; Tozzi, A.E.; De Giacomi, G.V. Effectiveness of an intervention program in reducing postoperative infections. Italian PRINOS Study Group. Am. J. Med., 1991, 91(3B), 164-169.
[8]
Nicastri, E.; Petrosillo, N.; Martini, L.; Larosa, M.; Gesu, G.P.; Ippolito, G. INF-NOS Study Group. Prevalence of nosocomial infections in 15 Italian hospitals: First point prevalence study for the INF-NOS project. Infection, 2003, 31(2), 10-15.
[9]
Zotti, C.M.; Messori Ioli, G.; Charrier, L.; Arditi, G.; Argentero, P.A.; Biglino, A.; Farina, E.C.; Moiraghi Ruggenini, A.; Reale, R.; Romagnoli, S.; Serra, R.; Soranzo, M.L.; Valpreda, M. Hospital Coordinator Group. Hospital-acquired infections in Italy: A region wide prevalence study. J. Hosp. Infect., 2004, 56(2), 142-149.
[10]
Di Pietrantonj, C.; Ferrara, L.; Lomolino, G. Multicenter study of the prevalence of nosocomial infections in Italian hospitals. Infect. Control Hosp. Epidemiol., 2004, 25(1), 85-87.
[11]
Moro, M.L.; Morsillo, F.; Tangenti, M.; Mongardi, M.; Pirazzini, M.C.; Ragni, P. ICN Regional Group. Rates of surgical-site infection: An international comparison. Infect. Control Hosp. Epidemiol., 2005, 26(5), 442-448.
[12]
Stein, G.E. Antimicrobial resistance in the hospital setting: Impact, trends, and infection control measures. Pharmacotherapy, 2005, 25(10), 44-54.
[13]
Cookson, B. Clinical significance of emergence of bacterial antimicrobial resistance in the hospital environment. J. Appl. Microbiol., 2005, 99(5), 989-996.
[14]
McDonald, L.C. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin. Infect. Dis., 2006, 42(2), 65-71.
[15]
Adler, A.; Friedman, N.D.; Marchaim, D. Multidrug-resistant gram-negative bacilli: Infection control implications. Infect. Dis. Clin. North Am., 2016, 30(4), 967-997.
[16]
Gerlich, M.G.; Piegsa, J.; Schäfer, C.; Hübner, N.O.; Wilke, F.; Reuter, S.; Engel, G.; Ewert, R.; Claus, F.; Hübner, C.; Ried, W.; Flessa, S.; Kramer, A.; Hoffmann, W. Improving hospital hygiene to reduce the impact of multidrug-resistant organisms in health care-a prospective controlled multicenter study. BMC Infect. Dis., 2015, 15, 441.
[17]
Chen, C.H.; Lin, L.C.; Chang, Y.J.; Chen, Y.M.; Chang, C.Y.; Huang, C.C. Infection control programs and antibiotic control programs to limit transmission of multi-drug resistant Acinetobacter baumannii infections: Evolution of old problems and new challenges for institutes. Int. J. Environ. Res. Public Health, 2015, 12(8), 8871-8882.
[18]
D’Alessandro, D.; Fabiani, M.; Cerquetani, F.; Orsi, G.B. Trend of Legionella colonization in hospital water supply. Ann. Ig., 2015, 27(2), 460-466.
[19]
Lautenbach, E.; Polk, R.E. Resistant gram-negative bacilli: A neglected healthcare crisis? Am. J. Health Syst. Pharm., 2007, 64(23), 3-21.
[20]
Maragakis, L.L.; Perencevich, E.N.; Cosgrove, S.E. Clinical and economic burden of antimicrobial resistance. Expert Rev. Anti Infect. Ther., 2008, 6(5), 751-763.
[21]
Levy, S.B.; Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med., 2004, 10(12), 122-129.
[22]
Sedláková, M.H.; Urbánek, K.; Vojtová, V.; Suchánková, H.; Imwensi, P.; Kolář, M. Antibiotic consumption and its influence on the resistance in Enterobacteriaceae. BMC Res. Notes, 2014, 7, 454.
[23]
Sabtu, N.; Enoch, D.A.; Brown, N.M. Antibiotic resistance: what, why, where, when and how? Br. Med. Bull., 2015, 116, 105-113.
[24]
Carlet, J. The world alliance against antibiotic resistance: consensus for a declaration. Clin. Infect. Dis., 2015, 60(12), 1837-1841.
[25]
Cohen, N.R.; Lobritz, M.A.; Collins, J.J. Microbial persistence and the road to drug resistance. Cell Host Microbe, 2013, 13(6), 632-642.
[26]
Pendleton, J.N.; Gorman, S.P.; Gilmore, B.F. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti Infect. Ther., 2013, 11(3), 297-308.
[27]
El-Mahallawy, H.A.; Hassan, S.S.; El-Wakil, M.; Moneer, M.M. Bacteremia due to ESKAPE pathogens: An emerging problem in cancer patients. J. Egypt. Natl. Canc. Inst., 2016, 28(3), 157-162.
[28]
Conte, M.P.; Venditti, M. Chiari ni, F.; d’Ettorre, G.; Zamboni, I.; Scoarughi, G.L.; Gallinelli, C.; Orsi, G.B. Extended spectrum beta lactamase producing Klebsiella pneumonia outbreaks during a 3rd generation cephalosporin restriction policy. J. Chemother., 2005, 17(1), 66-73.
[29]
Kollef, M.H.; Bassetti, M.; Francois, B.; Burnham, J.; Dimopoulos, G.; Garnacho-Montero, J.; Lipman, J.; Luyt, C.E.; Nicolau, D.P.; Postma, M.J.; Torres, A.; Welte, T.; Wunderink, R.G. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics and stewardship. Intensive Care Med., 2017, 43(9), 1187-1197.
[30]
Orsi, G.B.; Franchi, C.; Giordano, A.; Rocco, M.; Ferraro, F.; Mancini, C.; Venditti, M. Multidrug resistant Acinetobacter baumannii in an intensive care unit. J. Chemother., 2008, 20, 219-224.
[31]
Cosgrove, S.E.; Sakulas, G.; Perencevich, E.N.; Schwaber, M.J.; Karchmer, A.W.; Carmeli, Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis., 2003, 36(1), 53-59.
[32]
Vincent, J.L.; Rello, J.; Marshall, J.; Silva, E.; Anzueto, A.; Martin, C.D.; Moreno, R.; Lipman, J.; Gomersall, C.; Sakr, Y.; Reinhart, K. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA, 2009, 302(21), 2323-2329.
[33]
Marani, A.; Napoli, C.; Berdini, S.; Montesano, M.; Ferretti, F.; Di Ninno, F.; Orioli, R.; De Luca, A.; Sommella, L.; Tarsitani, G.; Orsi, G.B. Point prevalence survey on healthcare acquired infections in medical and surgical wards of a teaching hospital in Rome. Ann. Ig., 2016, 28(4), 274-281.
[34]
Garner, J.S.; Jarvis, W.R.; Emori, T.G.; Horan, T.C.; Hughes, J.M. CDC definitions for nosocomial infections. In: Olmsted R.N., ed: APIC infection control and applied epidemiology: Principles and Practice.. St Louis: Mosby, 1996; pp. A-1-A-20.
[35]
Wilson, M.L. General principles of specimen collection and transport. Clin. Infect. Dis., 1996, 22(5), 776-777.
[36]
Cohen Stuart, J.; Leverstein-Van Hall, M.A. Dutch working Party on the detection of highly resistant microorganisms. Guideline for phenotypic screening and confirmation of carbapenemases in Enterobacteriaceae. Int. J. Antimicrob. Agents, 2010, 36(3), 205-210.
[37]
Wayne, P.A. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 27th ed.. Clinical and Laboratory Standard Institute (CLSI),, 2017.
[38]
European Committee on Antimicrobial Susceptibility Testing. EUCAST breakpoint tables for interpretation of MIC’s and zone diameters.. http://www.eucast.org/clinical_breakpoints/ (Accessed August 7, 2018).
[39]
Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; Paterson, D.L.; Rice, L.B.; Stelling, J.; Struelens, M.J.; Vatopoulos, A.; Weber, J.T.; Monnet, D.L. Multidrug-resistant, extensively drug-resistant and pandrug-resistant becteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect., 2012, 18(3), 268-281.
[40]
Pittet, D.; Tarara, D.; Wenzel, R.P. Nosocomial bloodstream infection in critically ill patients: Excess length of stay, extra costs and attributable mortality. JAMA, 1994, 271, 1598-1601.
[41]
Vrijens, F.; Hulstaert, F.; Van de Sande, S.; Devriese, S.; Morales, I.; Parmentier, Y. Hospital-acquired, laboratory bloodstream infections: linking national surveillance data to clinical financial hospital data to estimate increased length of stay and healthcare costs. J. Hosp. Infect., 2010, 75(3), 158-162.
[42]
Holloway, K.A.; Rosella, L.; Henry, D. The impact of WHO essential medicines policies on inappropriate use of antibiotics. PLoS One, 2016, 11(3)e0152020
[43]
Pignatari, A.C.; Myake, M.M. TThe inappropriate use of antibiotics in upper respiratory tract infections: It is time for action. Braz. J. Otorhinolaryngol,, 2016, 82(2), 121-122.
[44]
Evirgen, O.; Onlen, Y.; Ertan, O. The intensity of antibiotic usage in the university hospital and the investigation of an inappropriate use of antibiotics. Bratisl. Lek Listy, 2011, 112(10), 595-598.
[45]
Al-Tawfiq, J.A.; Tambyah, P.A. Healthcare associated infections (HAI) perspectives. J. Infect. Public Health, 2014, 7(4), 339-344.
[46]
Pestotnik, S.L.; Classen, D.C.; Evans, R.S. Implementing antibiotic practice guidelines through computer assisted decision support: clinical and financial outcomes. Ann. Intern. Med., 1996, 124(10), 884-890.
[47]
La Russa, R.; Fineschi, V.; Di Sanzo, M.; Gatto, V.; Santurro, A.; Martini, G.; Scopetti, M.; Frati, P. Personalized medicine and adverse drug reactions: The experience of an Italian Teaching Hospital. Curr. Pharm. Biotechnol., 2017, 18(3), 274-281.
[48]
Huebner, C.; Roggelin, M.; Flessa, S. Economic burden of multidrug-resistant bacteria in nursing homes in Germany: A cost analysis based on empirical data. BMJ Open, 2016, 6(2)e008458
[49]
Zimlichman, E.; Henderson, D.; Tamir, O.; Franz, C.; Song, P.; Yamin, C.K.; Keohane, C.; Denham, C.R.; Bates, D.W. Health care-associated infections: A meta-analysis of costs and financial impact on the US health care system. JAMA Intern. Med., 2013, 173(22), 2039-2046.
[50]
Resch, A.; Wilke, M.; Fink, C. The cost of resistance: Incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur. J. Health Econ., 2009, 10(3), 287-297.
[51]
European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe, 2016.. https://ecdc.europa.eu/ sites/portal/files/documents/AMR-surveillance-Europe-2016.pdf (Accessed July 14, 2018).
[52]
European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe, 2014.. https://ecdc.europa.eu/ sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf (Accessed July 18, 2018).
[53]
Zsifkovits, J.; Zuba, M.; Geißler, W.; Lepuschütz, L.; Pertl, D.; Kernstock, E.; Ostermann, H. European Commission. Costs of unsafe care and cost effectiveness of patient safety programmes, 2016.. https://ec.europa.eu/health/sites/health/files/systems_performance_assessment/docs/2012_costs_psp_en.pdf (Accessed July 22, 2018).
[54]
Plowman, R. The socioeconomic burden of hospital acquired infection. Euro Surveill., 2000, 5(4), 49-50.
[55]
Mauldin, P.D.; Salgado, C.D.; Hansen, I.S.; Durup, D.T.; Bosso, J.A. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob. Agents Chemother., 2010, 54(1), 109-115.
[56]
Montagna, M.T.; Napoli, C.; Tafuri, S.; Agodi, A.; Auxilia, F.; Casini, B.; Coscia, M.F.; D’Errico, M.M.; Ferrante, M.; Fortunato, A.; Germinario, C.; Martinelli, D.; Masanotti, G.M.; Massenti, M.F.; Messina, G.; Montuori, P.; Mura, I.; Orsi, G.B.; Quaranta, A.; Sotgiu, G.; Stefanati, A.; Tardivo, S.; Torregrossa, M.V.; Tortorano, A.M.; Veronesi, L.; Zarrilli, R.; Pasquarella, C. Knowledge of undergraduate healthcare students about tuberculosis in 15 Italian university. BMC Public Health, 2014, 14, 970.
[57]
Orsi, G.B.; Vitali, M.; Marinelli, L.; Ciorba, V.; Tufi, D.; Del Cimmuto, A.; Ursillo, P.; Fabiani, M.; De Santis, S.; Protano, C.; Marzuillo, C.; De Giusti, M. Legionella control in the water system of antiquated hospital buildings by shock and continuous hyperchlorination: 5 years’ experience. BMC Infect. Dis., 2014, 14, 394.
[58]
Wakefield, D.S.; Pfaller, M.A.; Ludke, R.L.; Wenzel, R.P. Methods for estimating days of hospitalization due to nosocomial infections. Med. Care, 1992, 30, 373-376.
[59]
Haley, R.W.; Culver, D.H.; White, J.W.; Morgan, W.M.; Emori, T.G.; Munn, V.P.; Hooton, T.M. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am. J. Epidemiol., 1985, 121, 182-205.
[60]
Orsi, G.B.; Giuliano, S.; Franchi, C.; Ciorba, V.; Protano, C.; Giordano, A.; Rocco, M.; Venditti, M. Changed epidemiology of ICU acquired bloodstream infections over 12 years in an italian teaching hospital. Minerva Anestesiol., 2015, 81(9), 980-988.
[61]
Orsi, G.B.; Franchi, C.; Marrone, R.; Giordano, A.; Rocco, M.; Venditti, M. Laboratory confirmed bloodstream infection aetiology in an intensive care unit: Eight years study. Ann. Ig., 2012, 24, 269-278.
[62]
Anderson, D.J.; Kaye, K.S. Controlling antimicrobial resistance in the hospital. Infect. Dis. Clin. North Am., 2009, 23(4), 847-864.
[63]
Birgand, G.; Moore, L.S.P.; Bourigault, C.; Vella, V.; Lepelletier, D.; Holmes, A.H.; Lucet, J.C. Measures to eradicate multidrug-resistant organism outbreaks: How much do they cost? Clin. Microbiol. Infect., 2016, 22(2), 162.e1-162.e9.
[64]
Yates, R.R. New intervention strategies for reducing antibiotic resistance. Chest, 1999, 115(3), 24-27.
[65]
Spellberg, B.; Guidos, R.; Gilbert, D.; Bradley, J.; Boucher, H.W.; Scheld, W.M.; Bartlett, J.G.; Edwards, J., Jr Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of America. Clin. Infect. Dis., 2008, 46(2), 155-164.
[66]
Vrijens, F.; Hulstaert, F.; Devriese, S.; van de Sande, S. Hospital-acquired infections in Belgian acute-care hospitals: An estimation of their global impact on mortality, length of stay and healthcare costs. Epidemiol. Infect., 2012, 140(1), 126-136.
[67]
Macedo-Viñas, M.; De Angelis, G.; Rohner, P.; Safran, E.; Stewardson, A.; Fankhauser, C.; Schrenzel, J.; Pittet, D.; Harbarth, S. Burden of meticillin-resistant Staphylococcus aureus infections at a Swiss University hospital: Excess length of stay and costs. J. Hosp. Infect., 2013, 84(2), 132-137.
[68]
Kaye, K.S.; Marchaim, D.; Chen, T.Y.; Baures, T.; Anderson, D.J.; Choi, Y.; Sloane, R.; Schmader, K.E. Effect of nosocomial bloodstream infections on mortality, length of stay, and hospital costs in older adults. J. Am. Geriatr. Soc., 2014, 62(2), 306-311.
[69]
Primo, M.G.; Guilarde, A.O.; Martelli, C.M.; Batista, L.J.; Turchi, M.D. Healthcare-associated Staphylococcus aureus bloodstream infection: Length of stay, attributable mortality, and additional direct costs. Braz. J. Infect. Dis., 2012, 16(6), 503-509.
[70]
Rosenthal, V.D.; Guzman, S.; Migone, O.; Safdar, N. The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: A prospective, matched analysis. Am. J. Infect. Control, 2005, 33(3), 157-161.
[71]
Richards, M.J.; Edwards, J.R.; Culver, D.H.; Gaynes, R.P. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect. Control Hosp. Epidemiol., 2000, 21(8), 510-515.
[72]
Zhang, S.; Palazuelos-Munoz, S.; Balsells, E.M.; Nair, H.; Chit, A.; Kyaw, M.H. Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect. Dis., 2016, 16, 447.
[73]
Umscheid, C.A.; Mitchell, M.D.; Doshi, J.A.; Agarwal, R.; Williams, K.; Brennan, P.J. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect. Control Hosp. Epidemiol., 2011, 32(2), 101-114.
[74]
Borg, M.A. National cultural dimensions as drivers of inappropriate ambulatory care consumption of antibiotics in Europe and their relevance to awareness campaigns. J. Antimicrob. Chemother., 2012, 67(3), 763-767.
[75]
Rinaldi, A.; Marani, A.; Montesano, M.; Berdini, S.; Petruccioli, M.C.; Di Ninno, F.; Orioli, R.; Ferretti, F.; Tarsitani, G.; Napoli, C.; De Luca, A.; Orsi, G.B. Healthcare associated infections educational intervention by “Adult Learning” in an Italian teaching hospital. Ann. Ig., 2016, 28(6), 441-449.
[76]
Di Sanzo, M.; Cipolloni, L.; Borro, M.; La Russa, R.; Santurro, A.; Scopetti, M.; Simmaco, M.; Frati, P. Clinical applications of personalized medicine: A new paradigm and challenge. Curr. Pharm. Biotechnol., 2017, 18(3), 194-203.
[77]
Borro, M.; Gentile, G.; Cipolloni, L.; Foldes-Papp, Z.; Frati, P.; Santurro, A.; Lionetto, L.; Simmaco, M. Personalised healthcare: The DiMA clinical model. Curr. Pharm. Biotechnol., 2017, 18(3), 242-252.

Rights & Permissions Print Cite
Article Metrics
98
9
1
1
© 2024 Bentham Science Publishers | Privacy Policy